This is a multiple part, multiple cohort study evaluating the relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers.
Healthy, adult, male or female 19-55 years of age
Continuous non-smoker who has not used nicotine and tobacco-containing products for at least 3 months prior to the first dosing
Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2
Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, or 12-lead safety ECGs at the screening visit, as deemed by the PI or designee
Mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study
Clinically significant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neoplastic myeloproliferative, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine or connective tissue diseases or disorders
History of any gastrointestinal surgery or cholecystectomy that could impact the PK of NX-5948
History or presence of alcohol or drug abuse within the past 2 years